Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other Non-Current Assets (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Other Non-Current Assets data on record, last reported at $100000.0 in Q4 2025.

  • For Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $100000.0; the TTM value through Dec 2025 reached $100000.0, changed 0.0%, while the annual FY2025 figure was $100000.0, 0.0% changed from the prior year.
  • Other Non-Current Assets reached $100000.0 in Q4 2025 per INM's latest filing, roughly flat from $100000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $176637.0 in Q2 2022 and bottomed at $8625.0 in Q3 2021.
  • Average Other Non-Current Assets over 5 years is $111083.8, with a median of $100000.0 recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: soared 1884.12% in 2022, then plummeted 41.56% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $109175.0 in 2021, then surged by 56.75% to $171130.0 in 2022, then tumbled by 41.56% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $100000.0 in Q4 2025, $100000.0 in Q3 2025, and $100000.0 in Q2 2025.